- Hopper never extended twice - the last 2 anns put CHM in a similar league IMU is in - very likely that some like me transferred extra funds to get hands on shortfall - valued less than any other bio-comp on the ASX when comparing to number of assets and clinical trials progress - the first and now next to IMU the only CAR-T listed ASX bio and atm only one targeting solid cancer using CAR-T and having better data than current registered GBM drugs
When it runs, it will run hard. The past 4 weeks were a game changer, apart of the 2.8c.
GLTA
CHM Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)